Tang Capital Management HRMY Position
Active4-Fund ConvergenceTang Capital Management increased their position in Harmony Biosciences Holdings Inc. (HRMY) in Q4 2025, holding $10.9M worth of shares across 290,292 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
HRMY is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Pitolisant tablet in 106 days (Jul 31, 2026), making the timing of Tang Capital's position particularly relevant.
Short interest stands at 28.7% of float with 5.6 days to cover, indicating significant bearish positioning against Tang Capital's long thesis.
About Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Full company profile →Short Interest
28.7%
5.6 days to cover
Tang Capital Management HRMY Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 290,292 | +9,092 | $10.9M |
| Q3 2025 | Held | 281,200 | — | $7.8M |
| Q2 2025 | Held | 281,200 | — | $8.9M |
| Q1 2025 | Held | 281,200 | — | $9.3M |
| Q4 2024 | Held | 281,200 | — | $9.7M |
| Q3 2024 | Held | 281,200 | — | $11.2M |
| Q2 2024 | Held | 281,200 | — | $8.5M |
| Q1 2024 | Increased | 281,200 | +10,000 | $9.4M |
| Q4 2023 | Held | 271,200 | — | $8.8M |
| Q3 2023 | Held | 271,200 | — | $8.9M |
| Q2 2023 | Decreased | 271,200 | -50,000 | $9.5M |
| Q1 2023 | New | 321,200 | +321,200 | $10.5M |
Frequently Asked Questions
Does Tang Capital Management own HRMY?
Yes. As of Q4 2025, Tang Capital Management holds 290,292 shares of Harmony Biosciences Holdings Inc. (HRMY) valued at $10.9M. This data comes from their SEC 13F filing.
How many hedge funds own HRMY?
4 specialist biotech hedge funds currently hold HRMY, including Deep Track Capital, Perceptive Advisors, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy HRMY?
Tang Capital Management's position in HRMY was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's HRMY position increasing or decreasing?
Tang Capital Management increased their HRMY position in the most recent quarter, adding 9,092 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
HRMYCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →